Download PDF
Thromb Haemost 1995; 73(04): 584-591
DOI: 10.1055/s-0038-1653825
Original Articles
Clinical Studies
Schattauer GmbH Stuttgart

In Vitro Characterization of High Purity Factor IX Concentrates for the Treatment of Hemophilia B

Steven A Limentani
The Center for Hemostasis and Thrombosis Research, Division of Hematology and Oncology, Department of Medicine, New England Medical Center Hospitals and Tufts University School of Medicine, Boston, MA, USA
,
Kerry P Gowell
The Center for Hemostasis and Thrombosis Research, Division of Hematology and Oncology, Department of Medicine, New England Medical Center Hospitals and Tufts University School of Medicine, Boston, MA, USA
,
Steven R Deitcher
The Center for Hemostasis and Thrombosis Research, Division of Hematology and Oncology, Department of Medicine, New England Medical Center Hospitals and Tufts University School of Medicine, Boston, MA, USA
› Author Affiliations
Further Information

Publication History

Received 26 September 1994

Accepted after revision 02 December 1994

Publication Date:
09 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

This study employed sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis and immunoblotting to assess the purity of seven high purity factor IX concentrates: Aimafix (Aima), AlphaNine-SD (Alpha Therapeutic), Factor IX VHP (Biotransfusion), Immunine (Immuno), Mononine (Armour Pharmaceutical), Nanotiv (Kabi Pharmacia), and 9MC (Blood Products Laboratory). The mean specific activity of these products ranged from 68 U factor IX/mg (Aimafix) to 246 U factor IX/mg (Mononine). SDS-PAGE analysis showed that the highest purity product, Mononine, had a single contaminating band under non-reducing conditions. Two additional bands were detected when this product was analyzed under reducing conditions. All other products had multiple contaminating bands that were more apparent under reducing than non-reducing conditions. The immunoblot for factor IX showed a dominant factor IX band for all products. In addition, visible light chain of factor IX was detected for AlphaNine-SD, Factor IX VHP, Immunine, Mononine, Nanotiv, and 9MC, suggesting that the factor IX in these products had undergone partial activation to factor IXa. Another contaminating band was visible at 49,500 for all of the products except 9MC. In addition to this band, high molecular weight contaminants were apparent for some products, most notably AlphaNine-SD. The identity of these bands is unknown. Immunoblotting failed to demonstrate factor VII as a contaminant of any of the high purity products, although factor Vila could be detected in some lots of Immunine, Nanotiv, and 9MC by a clot-based assay. Factor X contaminated Aimafix, AlphaNine-SD, Factor IX VHP, Immunine, Nanotiv, and 9MC, but activation products of factor X were not detected. Prothrombin contaminated all of the products except Mononine. Activation products of prothrombin were identified for three of four lots of Immunine and for one lot of Factor IX VHP. These results thus demonstrate that high purity factor IX concentrates differ substantially in the degree to which they are contaminated by potentially thrombogenic materials.

 

  • References

  • 1 Pool JG, Shannon AE. Production of high-potency concentrates of antihemophilic globulin in a closed-bag system. NEJM 1965; 273: 1443
    CrossrefPubMedGoogle Scholar
  • 2 Tullis JL, Melin M, Jurigian P. Clinical use of human prothrombin complexes. NEJM 1965; 273: 667
    CrossrefPubMedGoogle Scholar
  • 3 Kasper CK. Clinical use of prothrombin complex concentrates: Report on thromboembolic complications. Thromb Diath Haemorrh 1975; 33: 640-644
    PubMedGoogle Scholar
  • 4 Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Sem Hematol 1991; 28 Suppl (Suppl. 06) 3-5
    PubMedGoogle Scholar
  • 5 White II GC, Roberts HR, Kingdon HS, Lundblad RL. Prothrombin complex concentrates: Potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo. Blood 1977; 49: 159
    PubMedGoogle Scholar
  • 6 Seligsohn U, Kasper CK, Osterud B, Rapaport SI. Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979; 53: 828
    PubMedGoogle Scholar
  • 7 Giles AR, Nesheim ME, Hoogendoorn H, Tracy PB, Mann KG. The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits. Blood 1982; 59: 401
    PubMedGoogle Scholar
  • 8 Kasper CK. Postoperative thrombosis in hemophilia B. NEJM 1973; 289: 160
    PubMedGoogle Scholar
  • 9 Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 1990; 76: 2540
    PubMedGoogle Scholar
  • 10 Kim HC, Matts L, Eisele J, Czachur M, Saidi P. Monoclonal antibody- purified factor IXcomparative thrombogenicity to prothrombin complex concentrate. Sem Hematol 1991; 28 Suppl (Suppl. 06) 15
    PubMedGoogle Scholar
  • 11 Kim HC, McMillan CW, White GC, Bergman GE, Horton MW, Saidi P. Purified factor IX using monoclonal immunoaffinity technique: Clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 1992; 79: 568
    PubMedGoogle Scholar
  • 12 Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. Br J Haematol 1991; 79: 606
    CrossrefPubMedGoogle Scholar
  • 13 Hampton KK, Preston FE, Lowe GD O, Walker ID, Sampson B. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate. Br J Haematol 1993; 84: 279
    CrossrefPubMedGoogle Scholar
  • 14 Bemtorp E, Bjorkman S, Carlsson M, Lethagen S, Nilsson IM. Biochemical and in vivo properties of high purity factor IX concentrates. Thromb Haemost 1993; 70: 768
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Limentani SA, Gowell KP. Evaluation of the purity and specific activity of two preparations of ultra-pure factor IX. Blood 1993; 82: 2369
    PubMedGoogle Scholar
  • 16 Herring SW, Abildgaard C, Shitanishi KT, Harrison J, Gendler S, Heldebrant CM. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety. J Lab Clin Med 1993; 121: 394-405
    PubMedGoogle Scholar
  • 17 Kasper CK, Abramson SB, Goldsmith JC, Herring S. In vivo recovery, halflife and safety of affinity purified solvent-detergent coagulation factor IX [Abstract]. Blood 1991; 78: 58 a
    PubMedGoogle Scholar
  • 18 Bumouf T, Michalski C, Goudemand M, Huart JJ. Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography. Vox Sang 1989; 57: 225-232
    PubMedGoogle Scholar
  • 19 Immunine product information. Immuno AG;
  • 20 Hrinda ME, Huang C, Tarr GC, Weeks R, Feldman F, Schreiber AB. Preclinical studies of a monoclonal antibody-purified factor IX, MononineTM. Semin Hematol. 1991. 28 6-14
    Google Scholar
  • 21 Löf A-L, Bemtorp E, Eriksson B, Mattson C, Svinhufvud L, Winge S, Östlin A. Characterization of a highly purified factor IX concentrate. In: Biotechnology of Blood Proteins. Rivat C, Stoltz J-F. eds Colloque INSERM/John Libbey Eurotext Ltd; 1993. pp 69-74
    Google Scholar
  • 22 Feldman PA, Harris L, Evans DR, Evans HE. Preparation of a high purity factor IX concentrate using metal chelate affinity chromatography. In: Biotechnology of Blood Proteins. Rivat C, Stoltz J-F. eds Colloque INSERM/John Libbey Eurotext Ltd; 1993. pp 63-68
    Google Scholar
  • 23 Fricke WA, Lamb MA. Viral safety of clotting factor concentrates. Semin Thromb Hemost 1993; 19: 54-61
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Bradford M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1977; 81: 485
    CrossrefPubMedGoogle Scholar
  • 25 Proctor RR, Rapaport SI. A partial thromboplastin time with kaolin: A simple screening test for first stage plasma clotting deficiencies. Am J Clin Pathol 1961; 36: 212
    CrossrefPubMedGoogle Scholar
  • 26 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 1970; 227: 680
    CrossrefPubMedGoogle Scholar
  • 27 Liebman HA, Limentani SA, Furie BC, Furie B. Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex. Proc Natl Acad Sci USA 1985; 82: 3879
    CrossrefPubMedGoogle Scholar
  • 28 Farrugia A, Oates A, Spiers D, Young I, Herrington R. A microtitre plate test for assessment of in-vitro thrombogenicity in factor IX concentrates using a chromogenic substrate. Throm Res 1989; 53: 191
    CrossrefPubMedGoogle Scholar
  • 29 Liebman HA, Furie BC, Furie B. The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor XIa. J Biol Chem 1987; 262: 7605
    PubMedGoogle Scholar
  • 30 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734
    PubMedGoogle Scholar
  • 31 Hrinda ME, Huang C, Tarr GC, Weeks R, Feldman F, Schreiber AB. Preclinical studies of a monoclonal antibody-purified factor IX, Mononine. Sem Hematol 1991; 28 Suppl (Suppl. 06) 6
    PubMedGoogle Scholar
  • 32 Seremetis SV, Aledort LM, Bergman GE, Bona R, Bray G, Brettler D, Eyster ME, Kessler C, Lau TS, Lusher J, Rickies F. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: Effects on immune status. Lancet 1993; 342: 700
    CrossrefPubMedGoogle Scholar
  • 33 Hay CR, McEvoy P, Duggan-Keen M. Inhibition of lymphocyte IL2-receptor expression by factor VIII concentrate: A possible cause of immunosuppression in haemophiliacs. Br J Haematol 1990; 75: 278
    CrossrefPubMedGoogle Scholar
  • 34 Thorpe R, Dilger P, Dawson NJ, Barrowcliffe TW. Inhibition of interleukin-2 secretion by factor VIII concentrates: A possible cause of immunosuppression in haemophiliacs. Br J Haematol 1989; 71: 387
    PubMedGoogle Scholar
  • 35 Cuthbert RJ, Ludlam CA, Steel CM, Beatson D, Peutherer JR. Immunological studies in HIV seronegative haemophiliacs: Relationships to blood product therapy. Br J Haematol 1992; 80: 364
    CrossrefPubMedGoogle Scholar
  • 36 Soria AG, Bouzas MB, Anselmo A, Ruibal-Ares BH. Modulation of allogeneic cytotoxic activity by factor VIII or IX concentrates. Haematologica 1991; 76: 33
    PubMedGoogle Scholar